The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! About 939,236 shares traded hands. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has declined 35.51% since March 8, 2016 and is downtrending. It has underperformed by 44.82% the S&P500.
The move comes after 7 months negative chart setup for the $714.95 million company. It was reported on Oct, 11 by Barchart.com. We have $5.00 PT which if reached, will make NASDAQ:ZIOP worth $50.05M less.
Analysts await ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report earnings on November, 7. They expect $-0.10 earnings per share, up 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.10 actual earnings per share reported by ZIOPHARM Oncology Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Ratings Coverage
Out of 3 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Ziopharm Oncology has been the topic of 5 analyst reports since December 4, 2015 according to StockzIntelligence Inc. The firm earned “Market Perform” rating on Wednesday, August 10 by Wells Fargo. As per Friday, December 4, the company rating was initiated by Wells Fargo. As per Monday, January 25, the company rating was maintained by Mizuho. The rating was initiated by Raymond James with “Market Perform” on Thursday, June 2. On Wednesday, May 11 the stock rating was maintained by Mizuho with “Neutral”.
According to Zacks Investment Research, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.”
ZIOP Company Profile
ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Firm is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.